EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 Feb 2023 16:42:44 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 Feb 2023 17:19:50 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 Feb 2023 02:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 Jan 2023 06:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 Jan 2023 17:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 Nov 2022 16:16:51 By Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 Nov 2022 16:05:14 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 Sep 2022 16:12:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

10 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

01 Aug 2022 16:05:47 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

18 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

07 Jul 2022 16:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

06 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

24 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

21 Jun 2022 06:30:00 By Nasdaq GlobeNewswire